High CSF CXCL13 concentration was confirmed in MS by several studies and associated with an increased risk of clinically definite MS and a more severe disease course in RRMS, SPMS, and PPMS patients [17–20]. This evidence concerns the gene CXCL13 and myeloid sarcoma.